Skip to main content

Overview

My current research focuses on understanding the molecular and cellular mechanisms driving the progression of interstitial lung disease (ILD) to pulmonary fibrosis, with particular emphasis on immune - stromal dysregulation and therapeutic target discovery using patient - derived biological samples.

I have over a decade of research experience spanning immunology, inflammation, molecular and cellular biology, lysosomal function, and translational biomedical research. Before joining Weill Cornell Medicine, I conducted postdoctoral research at Cornell University, where I investigated lysosomal protein homeostasis, glycosylation, and E3 ubiquitin ligase-mediated protein regulation using CRISPR-Cas9 gene editing and biochemical approaches. Previously, at Stanford University, my research contributed to identifying Enkurin as a potential biomarker for myeloproliferative neoplasms.

I earned my Ph.D. in Biochemistry from the University of Mysore, India, where I investigated the immunomodulatory functions of alpha-1-acid glycoprotein (AGP-1) and its distinct glycoforms in regulating inflammatory responses.

My technical expertise includes CRISPR-based gene editing, molecular biology, protein biochemistry, immunological assays, and disease-relevant cellular models. Beyond research, I am actively involved in scientific mentoring, peer review, and STEM outreach initiatives.

My long-term goal is to establish an independent translational research program focused on understanding how innate immune dysregulation and cellular dysfunction contribute to the development and progression of fibrotic lung diseases. Through this work, I aim to identify novel molecular targets and advance therapeutic strategies for patients with pulmonary fibrosis.

Publications

10 publications